WO2003057251A1 - Remedes contre l'arthrite - Google Patents

Remedes contre l'arthrite Download PDF

Info

Publication number
WO2003057251A1
WO2003057251A1 PCT/JP2002/013650 JP0213650W WO03057251A1 WO 2003057251 A1 WO2003057251 A1 WO 2003057251A1 JP 0213650 W JP0213650 W JP 0213650W WO 03057251 A1 WO03057251 A1 WO 03057251A1
Authority
WO
WIPO (PCT)
Prior art keywords
arthritis
remedies
antibody
egf
contain
Prior art date
Application number
PCT/JP2002/013650
Other languages
English (en)
French (fr)
Inventor
Tadafumi Tamura
Masako Uchii
Toshio Suda
Ichiro Miki
Akira Tanaka
Original Assignee
Kyowa Hakko Kogyo Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co., Ltd. filed Critical Kyowa Hakko Kogyo Co., Ltd.
Priority to US10/500,207 priority Critical patent/US7708999B2/en
Priority to JP2003557608A priority patent/JP4246069B2/ja
Priority to CA002471938A priority patent/CA2471938A1/en
Priority to DE60232101T priority patent/DE60232101D1/de
Priority to AT02792021T priority patent/ATE429249T1/de
Priority to KR1020047009998A priority patent/KR100942402B1/ko
Priority to AU2002361106A priority patent/AU2002361106B2/en
Priority to EP02792021A priority patent/EP1466623B1/en
Publication of WO2003057251A1 publication Critical patent/WO2003057251A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/JP2002/013650 2001-12-28 2002-12-26 Remedes contre l'arthrite WO2003057251A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US10/500,207 US7708999B2 (en) 2001-12-28 2002-12-26 Remedies for arthritis
JP2003557608A JP4246069B2 (ja) 2001-12-28 2002-12-26 関節炎の治療薬
CA002471938A CA2471938A1 (en) 2001-12-28 2002-12-26 Agent for treating arthritis
DE60232101T DE60232101D1 (ja) 2001-12-28 2002-12-26
AT02792021T ATE429249T1 (de) 2001-12-28 2002-12-26 Anti-fgf-8 antikörper gegen arthritis
KR1020047009998A KR100942402B1 (ko) 2001-12-28 2002-12-26 관절염 치료약
AU2002361106A AU2002361106B2 (en) 2001-12-28 2002-12-26 Remedies for arthritis
EP02792021A EP1466623B1 (en) 2001-12-28 2002-12-26 Anti-fgf-8 antibodies against arthritis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-400677 2001-12-28
JP2001400677 2001-12-28

Publications (1)

Publication Number Publication Date
WO2003057251A1 true WO2003057251A1 (fr) 2003-07-17

Family

ID=19189657

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/013650 WO2003057251A1 (fr) 2001-12-28 2002-12-26 Remedes contre l'arthrite

Country Status (11)

Country Link
US (1) US7708999B2 (ja)
EP (1) EP1466623B1 (ja)
JP (1) JP4246069B2 (ja)
KR (1) KR100942402B1 (ja)
CN (1) CN100389826C (ja)
AT (1) ATE429249T1 (ja)
AU (1) AU2002361106B2 (ja)
CA (1) CA2471938A1 (ja)
DE (1) DE60232101D1 (ja)
ES (1) ES2323949T3 (ja)
WO (1) WO2003057251A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2158315B1 (en) 2007-06-25 2016-03-23 ESBATech, an Alcon Biomedical Research Unit LLC Methods of modifying antibodies, and modified antibodies with improved functional properties
US10336820B2 (en) 2008-02-20 2019-07-02 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
ATE483799T1 (de) * 2006-06-09 2010-10-15 Hoffmann La Roche Hemmung der enzymatischen peroxidaseaktivität
US7662858B2 (en) 2008-05-23 2010-02-16 Aaipharma, Inc. Method of treating post-surgical acute pain
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
SG11202106073QA (en) * 2018-12-11 2021-07-29 Q32 Bio Inc Fusion protein constructs for complement associated disease
IL299048A (en) 2020-06-14 2023-02-01 Vertex Pharma Variants of complement factor - 1 fusion structures and preparations containing them and their uses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0799835A2 (en) * 1996-04-03 1997-10-08 Kyowa Hakko Kogyo Co., Ltd. Anti-fibroblast growth factor-8 monoclonal antibody
EP0882794A2 (en) * 1997-03-19 1998-12-09 Kyowa Hakko Kogyo Co., Ltd. Human complementarity determining region (CDR)-grafted antibody to ganglioside gm2
WO2000062809A1 (fr) * 1999-04-19 2000-10-26 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de proliferation cellulaire pour tumeurs androgeno-independantes
JP2001046066A (ja) * 1999-08-03 2001-02-20 Kyowa Hakko Kogyo Co Ltd 新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体
WO2003002608A1 (en) * 2001-06-28 2003-01-09 Kyowa Hakko Kogyo Co., Ltd. Humanized antibody against fibroblast growth factor-8 and fragment of the antibody

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5491220A (en) * 1993-09-24 1996-02-13 Yeda Research And Development Co., Ltd. Surface loop structural analogues of fibroblast growth factors
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
DK1632574T3 (da) * 1996-10-16 2011-02-28 Zymogenetics Inc Fibroblast-vækstfaktor homologer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0799835A2 (en) * 1996-04-03 1997-10-08 Kyowa Hakko Kogyo Co., Ltd. Anti-fibroblast growth factor-8 monoclonal antibody
EP0882794A2 (en) * 1997-03-19 1998-12-09 Kyowa Hakko Kogyo Co., Ltd. Human complementarity determining region (CDR)-grafted antibody to ganglioside gm2
WO2000062809A1 (fr) * 1999-04-19 2000-10-26 Kyowa Hakko Kogyo Co., Ltd. Inhibiteur de proliferation cellulaire pour tumeurs androgeno-independantes
JP2001046066A (ja) * 1999-08-03 2001-02-20 Kyowa Hakko Kogyo Co Ltd 新規な相補性決定領域を有するヒトｖｅｇｆ受容体ｋｄｒに対する抗体
WO2003002608A1 (en) * 2001-06-28 2003-01-09 Kyowa Hakko Kogyo Co., Ltd. Humanized antibody against fibroblast growth factor-8 and fragment of the antibody

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
HARAGUCHI R. ET AL., DEVELOPMENT, vol. 127, 2000, pages 2471 - 2479
KURIHARA YUKIKO ET AL.: "Cooperation of endothelin-1 and FGF8 in Meckel's cartilage formation", DEVELOPMENT GROWTH & DIFFERENTIATION, vol. 43, no. SUPPL., 2001, pages S109, XP002967004 *
LEWANDOSKI M. ET AL., NAT. GENET., vol. 26, 2000, pages 460 - 463
MANABE N. ET AL., RHEUMATOLOGY, vol. 38, 1999, pages 714 - 720
PRAUL CRAIG A. ET AL.: "Effect of fibroblast growth factors 1,2,4,5,6,7,8,9 and 10 on avian chondrocyte proliferation", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 84, no. 2, October 2001 (2001-10-01), pages 359 - 366, XP002967005 *
REMMERS E. F., GROWTH FACTORS, vol. 2, 1990, pages 179 - 188
SANO H. ET AL., J. CELL BIOL., vol. 110, 1990, pages 1417 - 1426
SATOH H. ET AL., J. BIOL. CHEM., vol. 273, 1998, pages 12307 - 12315
UCHINO M. ET AL., CLIN. ORTHOP., vol. 377, 2000, pages 119 - 125

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2158315B1 (en) 2007-06-25 2016-03-23 ESBATech, an Alcon Biomedical Research Unit LLC Methods of modifying antibodies, and modified antibodies with improved functional properties
US10336820B2 (en) 2008-02-20 2019-07-02 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof

Also Published As

Publication number Publication date
KR20040078652A (ko) 2004-09-10
DE60232101D1 (ja) 2009-06-04
US7708999B2 (en) 2010-05-04
ES2323949T3 (es) 2009-07-28
JPWO2003057251A1 (ja) 2005-05-12
AU2002361106A1 (en) 2003-07-24
EP1466623B1 (en) 2009-04-22
US20050175608A1 (en) 2005-08-11
CA2471938A1 (en) 2003-07-17
EP1466623A4 (en) 2006-05-17
JP4246069B2 (ja) 2009-04-02
ATE429249T1 (de) 2009-05-15
KR100942402B1 (ko) 2010-02-17
CN100389826C (zh) 2008-05-28
AU2002361106B2 (en) 2007-06-07
EP1466623A1 (en) 2004-10-13
CN1607961A (zh) 2005-04-20

Similar Documents

Publication Publication Date Title
WO2000064930A3 (en) Tribonectins
WO2005020899A3 (en) Substituted cycloalkyamine derivatives as modulators of chemokine receptor activity
WO2002060859A3 (en) Cyclic derivatives as modulators of chemokine receptor activity
WO2004032988A3 (en) Coupling agents for orthopedic biomaterials
AU4968397A (en) Antipruritic
TW200508224A (en) Cyclic derivatives as modulators of chemokine receptor activity
WO2005000332A3 (en) Therapeutic agent for soft tissue sarcoma
ES2182902T3 (es) Sistema de reparacion de superficies de articulaciones.
RS20060116A (en) Cyclic derivatives as modulators of chemokine receptor activity
WO2003007955A3 (en) Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
CY1109773T1 (el) Φαρμακα για ασθενειες των αρθρωσεων
BRPI0413468A (pt) inibidores de hmg-coa redutase baseados em pirrol
WO2002064125A3 (en) Use of a farnesoid x receptor antagonist for treating hyperlipidemia
MXPA03010327A (es) USO DE OSTEOPONTINA PARA TRATAMIENTO Y/O PREVENCIoN DE ENFERMEDADES NEUROLoGICAS.
EP1205189A3 (en) Combination of a prostaglandin agonist and a HMG-CoA reductase inhibitor for the stimulation of bone growth
WO2003057251A1 (fr) Remedes contre l'arthrite
DE602004029241D1 (de) Der chemokin-rezeptor-aktivität
WO2004071449A3 (en) Lactams as modulators of chemokine receptor activity
WO2002028829A3 (en) Peptide deformylase inhibitors
WO2004098516A3 (en) Cyclic derivatives as modulators of chemokine receptor activity
WO2005094268A3 (en) Treatment and prophylaxis of sepsis and septic shock
WO2002089788A3 (en) Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
WO2005028474A3 (en) Pyrazoloquinoline derivatives as chk-1 inhibitors
WO2004021987A3 (en) Treatment of rheumatoid arthritis by inhibition of pde4
EP1238669A3 (en) Neutrophil function inhibitors which contain glucosamine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003557608

Country of ref document: JP

Ref document number: 1020047009998

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2471938

Country of ref document: CA

Ref document number: 20028262905

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002361106

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002792021

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002792021

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10500207

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002361106

Country of ref document: AU